Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Gate AGSTU:BIG 30 Return-on-Tangible-Equity is -539.34% as of Dec. 2025. GuruFocus rates STU:BIG with a GF Score™ of 30/100. The stock has 7 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Bio-Gate AG ranks worse than 96.17% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bio-Gate AG's annualized net income for the quarter that ended in Dec. 2025 was €-0.66 Mil. Bio-Gate AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €0.12 Mil. Therefore, Bio-Gate AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -539.34%.
The historical rank and industry rank for Bio-Gate AG's Return-on-Tangible-Equity or its related term are showing as below:
STU:BIG'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -352.32 Med: -76.87 Max: -15.65
Current: -352.32
During the past 13 years, Bio-Gate AG's highest Return-on-Tangible-Equity was -15.65%. The lowest was -352.32%. And the median was -76.87%.
STU:BIG's Return-on-Tangible-Equity is ranked worse than 96.17% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs STU:BIG: -352.32
Bio-Gate AG (STU:BIG) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bio-Gate AG Return-on-Tangible-Equity Related Terms
Bio-Gate AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bio-Gate AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BIG vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Bio-Gate AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gate AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Gate AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bio-Gate AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -539.34% mean?
Bio-Gate AG (STU:BIG) has a Return-on-Tangible-Equity of -539.34% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bio-Gate AG and its competitors. According to the industry distribution chart, Bio-Gate AG ranks #729 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 96.2%.
Is Bio-Gate AG's Return-on-Tangible-Equity too high?
Bio-Gate AG's current Return-on-Tangible-Equity is -539.34%. Based on the distribution chart, Bio-Gate AG ranks #729 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio-Gate AG has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Gate AG's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Gate AG ranks #729 out of 758 companies for Return-on-Tangible-Equity. This places Bio-Gate AG in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bio-Gate AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gate AG's current Return-on-Tangible-Equity is -539.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gate AG stock overvalued right now?
Bio-Gate AG (STU:BIG) has a current Return-on-Tangible-Equity of -539.34%. The current Return-on-Tangible-Equity is -539.34%. Bio-Gate AG's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bio-Gate AG (STU:BIG), the current Return-on-Tangible-Equity is -539.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gate AG is a Germany based medical technology company. The company employs silver technology to endow materials and products with antimicrobial properties. It is focused on the medical technology products portfolio. In addition, its technologies are also used to refine cosmetics, consumer goods, and industrial products. The products of the company are plasma-coating, additives, textile solutions, spray, masterbatches, and others. The organization uses two different technologies; first, silver particles are incorporated into cosmetics, paints, veneers or plastics, and second involve coating final products like implants or wound dressings with a silver-containing functional layer.
30GF Score
Get the complete analysis for STU:BIG
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BIG has been successfully added to your 
